First Wave’s Adrulipase Disappoints In Third Phase II CF EPI Trial Despite New Formulation
Stock Down By 39%
The US firm’s lead gastrointestinal asset has missed the mark in a mid-stage exocrine pancreatic insufficiency trial in cystic fibrosis patients despite its best efforts to enhance the formulation after two prior setbacks.
